XNCR News and Press, Xencor Inc. From 08/02/22

Clinical-stage biotech Xencor, Inc. ( NASDAQ: XNCR ) and Irving, Texas-based molecular science company Caris Life Sciences unveiled a multi-year agreement on Tuesday to develop and commercialize XmAb bispecific antibodies targeted for the treatment of cancer patients. Per ...

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies PR Newswire IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ -- Caris Life Sciences ® (Cari...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after the market closes on Wednesday, August ...

Canaccord analyst William Maughan assumed coverage of Xencor ( XNCR ) with a Buy rating and $50 price target. Xencor has established itself as a premier antibody design company, with multiple partnerships across biopharma, Maughan tells investors. With a steady source of ...

Shares of Xencor have fallen by 46% since my 2019 update. I initially liked this one for "picks and shovels" aspect of the story. XmAb technology is being utilized by a variety of big pharmaceutical companies, with focus on bispecific antibodies and engineered cytokines. Xencor is...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb ® 104, a PD-1 x ICOS bis...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

Xencor, Inc. (XNCR) Q1 2022 Earnings Conference Call May 5, 2022 16:30 ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer Jo...

Xencor press release (NASDAQ:XNCR): Q1 GAAP EPS of $0.39 beats by $1.03. Revenue of $85.5M (+152.2% Y/Y) beats by $59.33M. Cash, cash equivalents, receivables and marketable debt securities totaled $683.6 million as of March 31, 2022, compared to $664.1 million on December 31, 2021. Based on ...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the firs...